ClinicalTrials.gg
RecruitingNCT06061926Updated Oct 23, 2024

Effect of Celery Seed on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

A Phase 2 interventional study of Celery Seed and Placebo in Metabolic Syndrome, sponsored by University of Guadalajara. Recruiting at 1 site in Mexico. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by University of Guadalajara · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled May 2023, registered Sep 2023).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Metabolic Syndrome by University of Guadalajara — 3 open to participants now, 3 under way, none of them phase 3. Metabolic Syndrome · University of Guadalajara.

Planned enrollment
4th of 13
28 · median 28
Started
2023
the only one that year
Phase 2
7 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Metabolic Syndrome by University of Guadalajara, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 7 in phase 2, and was the 11th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

3 of the 13 studies in Metabolic Syndrome by University of Guadalajara are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Metabolic Syndrome by University of Guadalajara, or all of them as a file.
02

Study summary

The Metabolic Syndrome (MS) is a cluster of cardiometabolic risk factors, which include abdominal obesity, hyperglycemia, dyslipidemia, and high blood pressure. MS is a global health problem, it represents a risk factor for the progression of cardiovascular disease, which constitute the main cause of mortality in the world and in Mexico. The current treatment involves lifestyle changes and pharmacological treatment for each of the components of MS, however, there is no single approved treatment to control all components. Celery seed (Apium graveolens L.) from the Apiaceae family contains the flavonoids apigenin and luteolin; essential oils such as d-limonene, selinene and phthalides such as 3-n-butylphthalide. Thanks to its bioactive components, celery seed has proven to be effective in treating individual MS disorders; however, most studies are in animal models and there are no clinical studies that evaluate its effectiveness on all components of the system. MS, insulin sensitivity and insulin secretion so it could appear as a new, safe and effective complementary therapy for the treatment of MS.

The aim of this study is to evaluate the effect of celery seed on the components of metabolic syndrome, insulin sensitivity, and insulin secretion.

Read the detailed description

A randomized, double-blind controlled clinical trial in 28 patients between 30 to 60 years of age with a diagnosis of MS according to the International Diabetes Federation (IDF) criteria without treatment and whether they voluntary accept participating and signing the informed consent.

Patients with one or more of the following criteria will be excluded: History of kidney, thyroid or liver disease; systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, fasting glucose ≥ 126 mg/dL, triglycerides ≥ 500 mg/dL, total cholesterol ≥240 mg/dL; pregnancy or lactation; consumption of medications or supplements with effects on the study variables.

Patients included, may be withdrawn from the study if they meet any of the following conditions: Withdrawal of the informed consent, treatment adherence \<80%, severe adverse reaction, intolerance or hypersensitivity to celery seed or placebo.

They will be assigned randomly two groups of 14 patients; one of the groups will receive 75 mg of celery seed twice at day (before breakfast and dinner) for 12 weeks.

The other group will receive homologated placebo (calcined magnesia) twice at day (before breakfast and dinner) for 12 weeks.

Waist circumference, blood pressure, fasting blood glucose, serum triglycerides and serum HDL cholesterol will be evaluated before and after intervention in both groups. Insulin sensitivity (Matsuda index), total insulin secretion (it is the result of the ratio between the area under the curve (AUC) of insulin in a 2-h OGTT and the AUC of glucose in a 2-h OGTT) and First phase of insulin secretion (Stumvoll index), will be calculated from the concentration of glucose and insulin obtained from an Oral Glucose Tolerance Test.

This protocol It´s already approved by the local ethics committee and written informed consent it´s going to be obtained from all volunteers.

Statistical analysis will be presented through measures of central tendency and dispersion, mean and deviation standard for quantitative variables; frequencies and percentage for qualitative variable. The analysis between groups (independent samples) will be analyzed using the Mann-Whitney U test for quantitative variables and the X2 test or Fisher's exact test for qualitative variables. The intragroup analysis (two related samples) will be performed using the Wilcoxon range test for quantitative variables. Statistical significance will be considered with a p\<0.05.

03

Conditions studied

  • Metabolic Syndrome

Keywords

  • Celery seed
  • Metabolic Syndrome
  • Insulin resistance
  • Insulin secretion
  • Insulin sensitivity
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients both sexes
  • Age between 30 and 60 years
  • Diagnosis of metabolic syndrome (MS) according to the IDF criteria: waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:

    • Fasting glucose ≥ 100 mg/dL
    • Triglycerides ≥150 mg/dL
    • HDL-c: Men ≤40 mg/dL, women ≤50 mg/dL
    • Blood pressure ≥130/85 mmHg
  • from 25 to 34.9 kg/m²
  • Stable weight at least the previous last 3 months (weight variation less than 10%)
  • No pharmacological treatment for MS, insulin sensitivity and insulin secretion
  • Acceptance and signing of

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Glucose ≥126 mg/dL
  • Total cholesterol ≥240 mg/dL
  • Triglycerides ≥500mg/dL
  • Systolic blood pressure ≥140 mmHg
  • Diastolic blood pressure ≥90 mmHg
  • Drugs or supplements consumption with proven properties that modify the behavior of the study variables.
  • History of kidney, liver or thyroid disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Celery seed

    14 patients to receive homologated intervention capsule (celery seed 150 mg) one capsule with 75 mg of celery seed, every 12 hours (before breakfast and before dinner) along 12 weeks.

    Drug: Celery Seed

  • Placebo comparator
    Placebo

    14 patients to receive homologated placebo capsule (calcinated magnesia) one capsule with calcinated magnesia, every 12 hours (before breakfast and before dinner) along 12 weeks.

    Drug: Placebo

Interventions

  • DrugCelery Seed

    Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.

    Also known as: Apium graveolens Leen

  • DrugPlacebo

    Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.

    Also known as: Calcined magnesia

06

What researchers measure

Primary outcomes

  1. Waist Circumference (WC)

    Waist Circumference will be evaluated at baseline and week 12 by World Health Organization technique

    Time frame: Baseline to week 12 (end of intervention)

  2. Systolic Blood Pressure (SBP)

    Systolic Blood Pressure (SBP) will be measured at baseline and week 12 with a digital sphygmomanometer three times in each arm to get an average

    Time frame: Baseline to week 12 (end of intervention)

  3. Diastolic Blood Pressure (DBP)

    Diastolic Blood Pressure (DBP) will be measured at baseline and week 12 with a digital sphygmomanometer three times in each arm to get an average

    Time frame: Baseline to week 12 (end of intervention)

  4. High-Density Lipoprotein (HDL-c)

    High density lipoprotein (HDL-c) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get c-HDL level

    Time frame: Baseline to week 12 (end of intervention)

  5. Fasting Blood Triglycerides Concentration (TG)

    Fasting Blood Triglycerides Concentration (TG) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get triglycerides concentration

    Time frame: Baseline to week 12 (end of intervention)

  6. Fasting Serum Glucose (FSG)

    The Fasting Serum Glucose (FSG) levels will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get fasting glucose level

    Time frame: Baseline to week 12 (end of intervention)

  7. Insulin Sensitivity (Matsuda Index)

    Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index to get insulin sensitivity

    Time frame: Baseline to week 12 (end of intervention)

  8. Total Insulin Secretion

    Total insulin secretion will be calculated at baseline and week 12. It is the result of the ratio between the AUC of insulin in a 2-h OGTT and the AUC of glucose in a 2-h OGTT. It allows estimating the proportion of total insulin secretion in relation to plasma glucose concentration.

    Time frame: Baseline to week 12 (end of intervention)

  9. First Phase of Insulin Secretion (Stumvoll Index)

    The first phase if insulin secretion will be calculated at baseline and week 12 with Stumvoll index to get first phase of insulin secretion

    Time frame: Baseline to week 12 (end of intervention)

Secondary outcomes

  1. Body weight

    Body weight will be measured at baseline and week 12 with a bioimpedance analysis

    Time frame: Baseline to week 12 (end of intervention)

  2. Body Mass Index (BMI)

    Body Mass Index (BMI) will be calculated at baseline and week 12 with the Quetelet index formula

    Time frame: Baseline to week 12 (end of intervention)

  3. Body Fat Percentage

    Body fat percentage will be measured at baseline and week 12 with a bioimpedance analysis

    Time frame: Baseline to week 12 (end of intervention)

  4. Total Cholesterol (TC)

    Total Cholesterol (TC) level will be evaluated at baseline and week 12 by enzymatic- colorimetric technique to get total cholesterol level

    Time frame: Baseline to week 12 (end of intervention)

  5. Low Density Lipoprotein (LDL-c)

    Low Density Lipoprotein (LDL-c) level will be calculated at baseline and week 12 with Friedewald formula to get LDL-c level

    Time frame: Baseline to week 12 (end of intervention)

  6. Very Low Density Lipoprotein (VLDL)

    Very Low Density Lipoprotein (VLDL) level will be calculated at baseline and week 12 with triglycerides concentration/5 formula to get VLDL level

    Time frame: Baseline to week 12 (end of intervention)

  7. Concentration of Blood Aspartate Aminostransferase (AST)

    Concentration of Blood Aspartate Aminostransferase (AST) level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get AST level

    Time frame: Baseline to week 12 (end of intervention)

  8. Alanine Aminotransferase (ALT)

    Concentration of Blood Alanine Aminostransferase (ALT) level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get ALT level

    Time frame: Baseline to week 12 (end of intervention)

  9. Creatinine

    Concentration of creatinine level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get creatinine level

    Time frame: Baseline to week 12 (end of intervention)

  10. Uric Acid

    Concentration of uric acid level will be evaluated at baseline and week 12 by enzymatic-colorimetric technique to get uric acid level

    Time frame: Baseline to week 12 (end of intervention)

  11. Incidence of treatment-Emergent Adverse Events

    Incidence of treatment-Emergent Adverse Events of celery seed or placebo will be identified by clinical evaluation from baseline week to week 12 with continuous surveillance

    Time frame: Baseline to week 12 (end of intervention)

  12. Tolerability to treatment

    Tolerability to treatment of celery seed or placebo will be identified by clinical evaluation from baseline week to week 12 with continuous surveillance

    Time frame: Baseline to week 12 (end of intervention)

07

Study locations

1 of 1 sites recruiting
  • INSTITUTO DE TERAPÉUTICA EXPERIMENTAL Y CLÍNICA. Centro Universitario de Ciencias de la Salud
    Guadalajara, Jalisco 44340, Mexico
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2025, 25 months after the start.

Of 28 non-industry phase 2 interventional studies under Metabolic Syndrome, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 62. This study's planned 25 months is below that.

Counting every sponsor, half of 31 studies reached it within 29 months; a quarter within 25 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Sep 29, 2023
StartActual
May 20, 2023
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2025
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06061926
Lead sponsor
University of Guadalajara
Responsible party
Karina Griselda Pérez Rubio (Principal Investigator, University of Guadalajara) — Principal investigator
First posted
Sep 29, 2023
Start date
May 20, 2023
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 23, 2024

Study contacts

Karina G Pérez Rubio, PhD
Contact
karina2410@hotmail.com
+523310585200 ext. 34212
Marisol Cortez Navarrete, PhD
Contact
cortez_marisol@hotmail.com
+523310585200 ext. 34212
Karina G Pérez Rubio, PhD
principal investigator · University of Guadalajara

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion